To Fight EID, Think Global, Act Local

• Our response to Emerging Diseases is considered on a global basis, but implementation is regional– The risk and impact of an EID is unique to a particular

region e.g. AHS in Europe– The need and type of intervention is unique to the region

e.g. FMD– The pathogen itself may have unique properties e.g. PRRS

• Achieving a rapid response requires planning and communication between industry and local and regional governments and regulatory authorities– Time lines to mass production of a vaccine can be

shortened if production and testing systems are already prepared

21/04/23 1

Pfizer Animal Health A Pfizer business

A leading global animal health company

Working to assure a safe, sustainable global food supply from healthy beef and dairy cattle, swine, poultry and fish

Helping dogs, cats and horses live healthierlonger lives

Pfizer Animal Health (PAH)

World leader in discovery, development, and manufacture of veterinary vaccines & medicines

700+ veterinary R&D scientists and specialists worldwide

Diverse portfolio of leading veterinary products & services for livestock & companion animals

Operating in 60+ countries

PAH Leader in Global R&D Investment

R&D Spend in $Millions

8102123

3945

78

103113120

165

200

PAH R&D $300 million +

Source: Vetnosis Income Statement Report, released September 2009

Mon- santoAlpharmaVeto- quinolCEVA J&JMerialI/SPPfizer(2010B)

Elanco Bayer Novartis BIV Virbac

PAH Global R&D Network

LincolnNebraska

Charles CityIowa

ThaneIndia

MelbourneAustralia

OlotSpain

Louvain-la-NeuveBelgium

KalamazooMichigan

SandwichUK

ZaventemBelgium

Complementary Businesses to Provide Total Solutions

Nutrition/Vitamins/Probiotics

Diagnostics

Genetics

BusinessServices

Generics

Tech Services

Innovative products

Aquaculture

Food Safety

PAH core businessPAH recently enteredPAH under evaluation

Rapid Development of H1N1 Vaccine for Swine

Pfizer Animal Health developed a vaccine with USDA supportto protect swine from the U.S. outbreak of the H1N1 virus

First industry partner to receive USDA approval for H1N1 vaccine Developed vaccine in a record 4-month period

Scientific Development Manufacturing Scale-up Commercial Justification Regulatory Approvals

Partnered with a ONE TEAM Approach across PAH and USDA

Prudent risk-taking & innovations Strain selection, parallel efforts in scale-up and clinical studies Manufacture of extensive supplies before market needs were

fully defined, Bioreactor, lyophilization cycle

PAH investment in EID vaccines

• EIDs are an increasing global health issue

• There is an increasing risk for new EIDs in the future:– Increasing global travel– Increasing world food trade– Increasing demand for protein

21/04/23 8

PAH investment in EID vaccines

• Louvain-La-Neuve facility has been identified as Pfizer’s European center of excellence for the development and production of vaccine solutions against emerging infectious diseases

• Offers advanced capabilities in development and production of vaccines both in expertise and equipment

• Is physically close to local and regional governments and regulatory authorities to facilitate frequent interaction and communication

21/04/23 9

Major Innovation in Pork Production

Favorable to animal welfare and the environment

Allows producers to raise pigs using less feed while enhancing meat quality

Avoids infections and complications that can be caused by physical castration

Improvac allows stakeholders across the pork production chain to reap the benefits of natural boar growth

Pfizer Animal Health in China

• Focus on PAH Goals – Working to assure a safe, sustainable global food supply from

health beef and dairy cattle , swine and fish – Help dogs , cats and horses live healthier and longer

• Introduce high quality animal products to local market – Improvac – Improve meat quality – Low dose and long acting antibiotic s - Draxxin and Excede – Low residue pharmaceutics products - Lincomix® Feed

Medication• The only FDA-approved antimicrobial treatment of ileitis and

mycoplasmal pneumonia with a zero-day withdrawal• Develop products fitting local need

– Identified need for local market – Initiate R&D work for local products